Get the Stockscreener App
2.34
13.59%
0.28
After Hours:
2.37
0.03
+1.28%
Palisade Bio Inc stock is traded at $2.34, with a volume of 5.82M.
It is up +13.59% in the last 24 hours and up +20.62% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.06
Open:
$2.09
24h Volume:
5.82M
Relative Volume:
1.40
Market Cap:
$392.23M
Revenue:
$250.00K
Net Income/Loss:
$-16.78M
P/E Ratio:
-1.576
EPS:
-1.4848
Net Cash Flow:
$-10.85M
1W Performance:
+25.13%
1M Performance:
+20.62%
6M Performance:
+35.26%
1Y Performance:
+246.87%
1-Day Range:
$2.09
$2.35
1-Week Range:
$1.79
$2.35
52-Week Range:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.34 | 345.30M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Piper Sandler reiterates Overweight rating on Palisade Bio stock - Investing.com UK
Piper Sandler reiterates Overweight rating on Palisade Bio stock By Investing.com - Investing.com India
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - The Manila Times
Palisade Bio CEO, CMO to give virtual Needham presentation April 16 - Stock Titan
Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN
Earnings Miss: Can Palisade Bio Inc expand its profit margins2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
PALI Should I Buy - Intellectia AI
Palisade Bio partners with Iterative Health to advance PALI-2108 - TipRanks
Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - Investing.com Australia
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView — Track All Markets
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
Palisade Bio, Inc. (PALI) stock price, news, quote and history - Yahoo Finance UK
Clear Street Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail
Clear Street reiterates Palisade Bio stock rating on trial data By Investing.com - Investing.com South Africa
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - moomoo.com
Clear Street reiterates Palisade Bio stock rating on trial data - Investing.com
Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - marketscreener.com
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals - MarketBeat
Support Test: Can Palisade Bio Inc beat the S P 500Market Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Palisade Bio posts trial data for lead asset (PALI:NASDAQ) - Seeking Alpha
Crafting a New Financial Era: Palisade Bio Inc.’s Strategic Moves - StocksToTrade
Palisade Bio stock maintains buy rating at Stifel on trial data - Investing.com Australia
Palisade Bio stock maintains buy rating at Stifel on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - moomoo.com
Palisade Bio reports Phase 1b trial results for Crohn’s drug By Investing.com - Investing.com South Africa
Palisade Bio reports Phase 1b trial results for Crohn’s drug - Investing.com
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease - GlobeNewswire
HC Wainwright Forecasts Palisade Bio Q1 Earnings - MarketBeat
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI) - marketbeat.com
Palisade Bio, Inc. announced that it has received $3 million in funding from Iterative Scopes, Inc. - marketscreener.com
Big Picture: Can Palisade Bio Inc expand its profit marginsMarket Performance Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating - Seeking Alpha
Palisade Bio 2026 10-K: Clinical Development, Risk Factors, and Precision Medicine Strategies for IBD - Minichart
Aug Spikes: Can Palisade Bio Inc expand its profit marginsQuarterly Earnings Report & Weekly Return Optimization Alerts - baoquankhu1.vn
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS - MarketBeat
Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Palisade Bio 10-K: Net loss $16.8M, EPS $(0.30) - TradingView
[10-K] PALISADE BIO, INC. Files An... - Stock Titan
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients - Insider Monkey
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):